Richard Scartozzi, MD
Retina Specialist · Danbury, CTNPI 1487688826
Payments from drug & device makers
Across 157 payments — averaging $4417.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Apellis Pharmaceuticals, Inc.$241K
- Boehringer Ingelheim$236K
- Novartis$109K
- Eyepoint US, Inc.$102K
- Boehringer Ingelheim International GmbH$5K
- Vertex$440
- plus $1K from 11 others
Across 2 payments — averaging $62.93 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim International GmbH$126
What the payments were for
- Consulting fees$79545%
- Speaking & faculty fees$18811%
- Food & beverage$78544%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Apellis Pharmaceuticals, Inc. | 58 | $240,740 |
| Boehringer Ingelheim | 17 | $235,766 |
| Novartis | 5 | $108,552 |
| Eyepoint US, Inc. | 2 | $101,661 |
| Boehringer Ingelheim International GmbH | 41 | $5,254 |
| Vertex | 3 | $440 |
| Endo USA, Inc. | 1 | $330 |
| Regeneron Healthcare Solutions, Inc. | 12 | $299 |
| Mckesson Corporation | 1 | $188 |
| AbbVie | 5 | $107 |
| Bausch & Lomb Americas Inc. | 3 | $68 |
| Genentech USA, Inc. | 3 | $62 |
| Alcon | 2 | $38 |
| Astellas Pharma US Inc | 1 | $34 |
| Lombart Brothers, Inc. | 1 | $29 |
| Oyster Point Pharma, Inc. | 1 | $21 |
| Thea Pharma Inc. | 1 | $20 |
How this compares
Too few retina specialist providers in Connecticutto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ProlensaBromfenac Sodium | 45 | $18,917 |
| IlevroNepafenac | 32 | $11,897 |
| Bromfenac Sodium | 45 | $11,749 |
| LumiganBimatoprost | 14 | $8,522 |
| Prednisolone Acetate | 39 | $1,400 |
| Brimonidine Tartrate | 20 | $1,237 |
| Latanoprost | 67 | $857 |
| Ketorolac Tromethamine | 13 | $279 |
| Dorzolamide Hcl | 12 | $165 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisIlevro | $108,552 | $11,89732 claims |
| AbbVieLumigan | $107 | $8,52214 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few retina specialist providers in Connecticuton file to place this against a meaningful peer group, so we don't.
Other retina specialist in Danbury
- Armand DaccacheDanbury$3K
- Vincent ReppucciDanbury$1K
- Nauman ChaudhryWaterford$7.3M
- Juner Colina BiscottoWaterford$686K
- Scott WalterManchester$312K
- Greg BudoffManchester$5K
- Stephanie SuginWaterbury$2K
- Craig SklarWaterbury$2K
- Tomasz WiraszkaWaterbury$2K
- Jennifer NadelmannNew Haven$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.